Streetbeat News

Earnings

WKHS

Workhorse Group reported Q4 losses of $(0.19) per share, missing the $(0.09) estimate, but sales of $4.41M exceeded the $3.24M estimate. This represents a 20.83% decrease in losses and a 27.81% increase in sales year-over-year.

Portfolio Pulse from Happy Mohamed

March 12, 2024 | 1:01 pm

VEEV

17 analysts have recently shared their evaluations of Veeva Systems (NYSE:VEEV), showing a mix of bullish and bearish sentiments. The average 12-month price target is $241.06, reflecting a 12.03% increase from the previous target of $215.18. Analysts from firms like Morgan Stanley, Keybanc, and Jefferies have adjusted their ratings and price targets, indicating a positive outlook for VEEV. The company, a leading provider of cloud-based solutions for the life sciences industry, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, despite lagging behind its industry peers in revenue growth rate.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 1:00 pm

INZY

Inozyme Pharma (INZY) reported a narrower FY23 EPS loss of $(1.37) compared to $(1.78) YoY. The company's cash position was strong at $188.6M as of Dec 31, 2023, expected to support operations into Q4 2025. R&D expenses increased to $54.8M, primarily due to costs related to ongoing clinical trials and potential commercialization. G&A expenses remained flat at $20.8M. The net loss for FY23 was $71.2M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:00 pm

KA

MRK

Kineta's shares surged following an update on its VISTA-101 Phase 1/2 clinical trial for KVA12123, both as a monotherapy and combined with Merck's KEYTRUDA, targeting advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:00 pm

MTN

Vail Resorts' stock price declined following the announcement of disappointing Q2 financial results and a reduction in the fiscal 2024 guidance.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:58 pm

ASAN

Asana's stock price is trading lower due to the company providing weaker than expected revenue guidance for fiscal year 2025.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:58 pm

ICU

SeaStar Medical Holding Corporation (NASDAQ:ICU) provided updates on its acute kidney injury (AKI) programs, including the enrollment of 21 subjects in its NEUTRALIZE-AKI clinical trial for adult AKI patients. The trial aims to enroll up to 200 adults to evaluate the safety and efficacy of its Selective Cytopheretic Device (SCD) therapy. Additionally, the FDA granted a Humanitarian Device Exemption Approval Order for its Quelimmune pediatric device for AKI due to sepsis, with plans to expand commercial rollout with Nuwellis, Inc. in Q2. The company also plans a business update conference call in April.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:57 pm

MANU

Manchester United shares experienced an increase in trading following the announcement of their Q2 financial results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:57 pm

MANU

Manchester United reported its Q2 2024 adjusted earnings per share (EPS) at $0.15, surpassing the estimated $(17.00). Sales reached $280.280 million, also beating the $173.000 million estimate.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:56 pm

HRTG

Heritage Insurance Holdings' shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:56 pm